

Vojta therapy in multiple sclerosis rehabilitation

| | | |
|--|--|--|
| Submission date 05/02/2022 | Recruitment status No longer recruiting | <input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 16/02/2022 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results |
| Last Edited 16/02/2022 | Condition category Nervous System Diseases | <input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Background and study aims

Multiple sclerosis (MS) is one of the most common causes of neurological disability that affects young adults. It is a lifelong condition that affects the brain and nerves. Gait and balance problems are one of the most common symptoms of the disease even in the early stages, affecting more than 75% of people with MS. These problems affect gait, with a great risk of falling, and also affect most daily life activities, with a great impact on quality of life. Therefore, attention to this problem has to be taken as a priority. The aim of this study will be to compare the short- and long term effects of Vojta therapy and standard rehabilitation on gait, balance, postural control and pain.

Who can participate?

Patients aged 18 years and over with chronic low back pain

What does the study involve?

Participants will be randomly allocated to receive Vojta therapy or standard rehabilitation, 10 times in total. Gait, body balance, muscle pain and postural control will be measured before and after treatment and during follow-up visits 1 and 3 months after the end of the study.

What are the possible benefits and risks of participating?

Participants will receive a complete treatment program, which may lead to improved gait, body balance and postural control and reduced muscle pain. Risks include temporary fatigue up to 24 hours after the first exercise procedures.

Where is the study run from?

1. University of Opole (Poland)
2. Malgorzata Fuchs Fizjoterapia (Opole)

When is the study starting and how long is it expected to run for?

August 2021 to December 2023

Who is the main contact?

1. Lukasz Argier, PT, MSc

argier@o2.pl
2. Prof. Jakub Taradaj
j.taradaj@awf.katowice.pl

Contact information

Type(s)

Public

Contact name

Mr Lukasz Argier

Contact details

Nowoczesna Fizjoterapia Neurar
Zwyciestwa 2/86 Street
Opole
Poland
45-855
+48 (0)606781243
argier@o2.pl

Type(s)

Scientific

Contact name

Prof Jakub Taradaj

ORCID ID

<http://orcid.org/0000-0002-1796-5832>

Contact details

Academy of Physical Education
72 Mikolowska Street
Katowice
Poland
40-065
+48 (0)668613945
j.taradaj@awf.katowice.pl

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Study information

Scientific Title

Vojta therapy improves gait and postural control in multiple sclerosis rehabilitation

Acronym

VojtaNDT & MS

Study objectives

1. Vojta therapy improves gait parameters in multiple sclerosis (MS) patients compared to standard rehabilitation
2. Vojta stimulation is effective in muscle pain relief in MS
3. The Vojta approach improves body balance, stability and postural control of MS patients compared to the standard program

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 08/10/2021, Research Ethics Committee from Wroclaw Medical University (1 Pasteur Street, 50-367, Wroclaw, Poland; +48 (0)717841014; bioetyka@umed.wroc.pl), ref: KB-807/2021

Study design

Prospective randomized clinical study with follow-up analysis

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Multiple sclerosis

Interventions

After baseline assessments, the participants will be randomly assigned to:

1. Vojta therapy
2. Standard rehabilitation training

The individuals receiving the treatment will be blinded. A computer-generated list of random numbers will be used and concealed from the researchers enrolling and assessing the participants. The outcome assessors and data analysts will be kept blinded to the allocation

The treatment protocol in the first group will include NDT Vojta exercises (once a day, three days a week) within 3 weeks. Each session will consist of a 40-min Vojta therapy protocol based on three exercises: crawling reflex and 1st phase and 2nd phase rolling reflex. The three face to face sessions will be made by the principal investigator. The participants in the second group will receive the standard rehabilitation program (50 minutes, once a day, three days a week) within 3 weeks, including balance exercises targeting core stability, exercises of coordination and proprioceptive neuromuscular facilitation (PNF) as well as individual sessions using the Bobath concept.

Intervention Type

Behavioural

Primary outcome measure

Gait analysed using a medical treadmill at baseline, 4, 8 and 16 weeks

Secondary outcome measures

1. Pain assessed with the Visual Analogue Scale at baseline, 4, 8 and 16 weeks
2. Balance and postural control assessed with the Berg Balance Scale (BBS) and the Tinetti Test at baseline, 4, 8 and 16 weeks
3. Postural control measured using the Timed Walking Test and 12-item Multiple Sclerosis Walking Scale at baseline, 4, 8 and 16 weeks

Overall study start date

16/08/2021

Completion date

30/12/2023

Eligibility

Key inclusion criteria

1. Final diagnosis of MS (by McDonald's criteria)
2. Relapsing-remitting stage of MS
3. Walkability with or without assistance (4.0-6 in Expanded Disability Status Scale [EDSS])

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

50

Key exclusion criteria

1. Younger than 18 years old
2. Progressive MS
3. Phase outbreak or outbreak in the 3 months before the study
4. Medication that prevents or limits the performance of the locomotion reflex
5. Non-treated arterial hypertension
6. Cardiopulmonary incompetence
7. Pregnancy
8. Cancer
9. Active infections
10. Hepatitis B and HIV infection
11. Severe articular degeneration, including patients eligible for orthopedic surgery
12. Advanced osteoporosis
13. A history of stroke and Parkinson disease

Date of first enrolment

07/03/2022

Date of final enrolment

28/07/2023

Locations

Countries of recruitment

Poland

Study participating centre

University of Opole

Institute of Health Sciences
68 Katowicka Street
Opole
Poland
45-065

Study participating centre

Małgorzata Fuchs Fizjoterapia

7 Grota Roweckiego
Opole
Poland
45-268

Sponsor information

Organisation

Opole University

Sponsor details

Institute of Health Sciences

Katowicka 68 Street

Opole

Poland

45-060

+48 (0)77 44 23 546

bozena.ratajczakolszewska@uni.opole.pl

Sponsor type

University/education

Website

<https://wnoz.uni.opole.pl/>

ROR

<https://ror.org/04gbpnx96>

Funder(s)**Funder type**

Hospital/treatment centre

Funder Name

Nowoczesna Fizjoterapia Neurar

Results and Publications**Publication and dissemination plan**

Publications in peer-reviewed journals

Intention to publish date

30/12/2023

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request (j.taradaj@awf.katowice.pl)

IPD sharing plan summary

Available on request